The first selective EZH2 inhibitor (tazemetostat) was developed, which demonstrated antitumor activity in B-cell non-Hodgkin lymphoma cell lines and was approved for EZH2-mutated follicular lymphoma [114]. This evidence concerns the gene EZH2 and follicular lymphoma.